Medisafe

Overview

Medisafe is a digital companion and medication-management platform for pharma-sponsored patient engagement programs. The company is relevant to launch teams when a brand needs patient activation after prescription: education, reminders, appointment and dose tracking, support-program enrollment, persistence engagement, and feedback into the broader patient-services stack.

Medisafe should not be evaluated as a hub vendor, specialty pharmacy, copay administrator, or outsourced case-management team. It is a technology layer that can sit beside those partners when the commercial problem is sustained engagement rather than access execution alone.

Engagement & Adherence Capability Model

The framework below standardizes how Rx Almanac evaluates patient-engagement-adherence capabilities, so buyers can compare vendors like-for-like while the readout column stays vendor-specific. For this table, Medisafe is evaluated as digital companion and medication-management platform for pharma-sponsored patient engagement programs.

Capability	Buyer should compare	Medisafe readout
Behavioral segmentation and journey design	Patient segmentation, barrier identification, journey mapping, personalization rules, and intervention timing.	Documented, validate method. Medisafe positions around behavioral science and just-in-time interventions; buyers should inspect the rules, segmentation model, and evidence behind each program.
Omnichannel patient communications	SMS, email, web, app, phone, print, and caregiver / HCP communications with consent management.	Core engagement model. Public materials describe app, web, text, wearables, tablets, and AI voice outreach. Channel mix, consent handling, and opt-out logic should be demoed.
Adherence coaching and persistence analytics	Refill reminders, adherence risk scoring, persistence tracking, motivational support, and outcomes measurement.	Core engagement model. Medication routines, reminders, adherence engagement, and persistence are central to the platform; require therapy-specific cohorts and analytic methodology.
Care-team escalation and human support	Nurse, coach, call-center, or case-manager escalation when digital nudges are insufficient.	Partner-dependent. Medisafe can support escalation workflows, but human staffing usually remains with the manufacturer, hub, nurse educator, or services partner.
Education content and program measurement	Disease education, onboarding content, MLR-ready materials, survey instruments, and performance reporting.	Documented, validate governance. Visible manufacturer programs support branded education and companion apps; buyers should review MLR controls, adverse-event handling, and content-update workflows.
Hub, pharmacy, and CRM integration	Data exchange with hubs, specialty pharmacies, CRM, EHR, claims, and manufacturer reporting environments.	Core diligence area. Medisafe is most valuable when it integrates with the hub and CRM stack instead of creating a disconnected patient app.

Buyer Fit

• Shortlist when: Include Medisafe when a specialty or complex-therapy brand needs a branded digital companion, patient-support enrollment activation, adherence engagement, or patient-facing education layer.
• Strong fit: Programs where reminders, appointment coordination, caregiver support, dose tracking, and patient education influence persistence or safe therapy continuation.
• Overlay fit: Pair with a hub, CRM, specialty pharmacy, agency, or nurse educator vendor when Medisafe owns the digital engagement layer and other partners handle access or human escalation.
• Less natural fit: Full hub outsourcing, prior authorization execution, copay administration, free-drug fulfillment, specialty dispensing, or a purely human nurse-educator program.
• Commercial fit: Expect custom scoping around branded content, integrations, consent, patient data returns, adverse-event workflows, multilingual support, AI voice use, and outcomes reporting.

Differentiators

• Digital companion orientation: Medisafe is built around patient-facing medication routines and support journeys rather than back-office hub work queues.
• Visible manufacturer programs: Eisai / Biogen and EMD Serono provide public signals that the platform can support pharma-sponsored programs, not only consumer medication reminders.
• Omnichannel expansion: Medisafe now positions across app, text, web, wearables, tablets, and voice rather than a single mobile-app channel.
• AI voice layer: VIA gives the company a current 2025 product story around enrollment friction and patient-support activation.
• Research footprint: The MedISAFE-BP randomized trial and later adherence-app literature give buyers evidence to discuss, while still requiring therapy-specific validation before using outcomes in a launch forecast.

RFP Questions

• Which parts of the patient support journey will Medisafe own directly, and which remain with the hub, CRM, agency, specialty pharmacy, or manufacturer team?
• What patient-level data flows back to the manufacturer, and how are consent, HIPAA, opt-outs, caregiver access, and channel preferences managed?
• How are adverse events, product complaints, off-label messages, and urgent clinical escalations detected and routed?
• Which integrations are live today with Salesforce, Veeva, hub platforms, specialty pharmacies, EHRs, and manufacturer data lakes?
• What is configured in Maestro versus custom-built, and what can launch within the required timeline?
• How does VIA disclose AI voice interactions, handle multilingual conversations, and preserve auditable transcripts?
• What therapy-specific evidence can Medisafe show for starts, persistence, adherence, abandonment, or engagement lift?
• How does the program address app fatigue and long-term engagement decay after the first months of therapy?

Recent Activity

• 2026-05 - Current Medisafe materials emphasize Maestro, JITI, VIA, therapeutic-area programs, and companion-app deployments while preserving the boundary against hub, copay, or dispensing operations.

• October 2025: Eisai and Biogen described the LEQEMBI Companion app as developed with Medisafe to support patients and care partners through treatment.

• April 2025: Medisafe launched VIA, an AI voice assistant for patient onboarding, enrollment, adherence, and support-program activation.

• March 2025: Medisafe announced a strategic multi-year collaboration with EMD Serono to launch the HIV Resource Center by Medisafe.

• September 2024: Medisafe announced an omnichannel expansion for life-sciences companies across app, web, text, wearables, and tablet channels.

• February 2021: Medisafe raised a $30 million Series C led by Sanofi Ventures and ALIVE Israel HealthTech Fund.